Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference

HOPKINTON, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE) today announced that Peter Savas, Chairman and CEO of Alseres Pharmaceuticals, Inc., will present Monday, November 10th at 2:00pm ET at Rodman & Renshaw Annual Healthcare Conference at the New York Palace Hotel in New York providing an overview on the Company and its therapeutic programs.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

    A live webcast will be available at:
    http://www.wsw.com/webcast/rrshq14/alse

    For more information on the conference and speaking companies please go to

    http://www.rodm.com/conferences?id=19

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Alseres, Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

    Contact:
    Sharon Correia - 508-497-2360 ext. 224
    Alseres Pharmaceuticals, Inc.
    scorreia@alseres.com

    Adam Friedman - 212-981-2529 ext. 18
    Adam Friedman Associates
    adam@adam-friedman.com